Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Corporativo Fragua operates as a pharmaceutical distribution and retail pharmacy network in Mexico, functioning as a critical intermediary between manufacturers and end consumers. The company's competitive position relies on logistics infrastructure, regional density in key Mexican markets, and relationships with both pharmaceutical suppliers and healthcare providers. Stock performance is driven by prescription volume trends, generic drug penetration rates, and operating margin expansion through distribution efficiency.
Fragua generates revenue through buy-sell spreads on pharmaceutical products, capturing margins of 3-8% on wholesale distribution and 20-30% on retail pharmacy sales. The business model depends on high inventory turnover (8-12x annually), route density to minimize delivery costs, and scale advantages in supplier negotiations. Pricing power is limited by government price controls on essential medicines and competitive pressure from other distributors, but the company benefits from sticky customer relationships due to service reliability and product availability. Operating leverage comes from fixed distribution infrastructure that can absorb volume growth with minimal incremental cost.
Mexican prescription drug market growth rates, driven by healthcare coverage expansion and chronic disease prevalence
Generic drug substitution trends and government policies promoting biosimilar adoption
Operating margin trajectory from distribution efficiency gains and retail pharmacy mix shift
Working capital management and days inventory outstanding, critical given 23.4% gross margins
Competitive dynamics with other Mexican distributors (Nadro, Casa Saba) and potential market share shifts
Mexican government healthcare reforms and potential implementation of centralized pharmaceutical procurement that could disintermediate private distributors
Direct-to-consumer pharmaceutical e-commerce growth from manufacturers or pure-play digital pharmacies bypassing traditional distribution
Regulatory price controls on essential medicines limiting margin expansion potential and creating revenue pressure during inflationary periods
Market share erosion to larger competitors with superior scale economics and technology investments in supply chain optimization
Vertical integration by large hospital systems or pharmacy chains developing captive distribution capabilities
Amazon or other tech-enabled entrants disrupting pharmaceutical distribution through superior logistics and customer experience
Working capital intensity creating cash flow volatility if inventory turnover deteriorates or customer payment terms extend
High capex requirements ($4.6B against $4.7B operating cash flow) limiting financial flexibility and dividend capacity, with only $0.1B free cash flow generation
low - Pharmaceutical demand is relatively non-discretionary, driven by medical necessity rather than economic conditions. However, economic downturns can shift mix toward lower-priced generics and reduce elective medication adherence. Mexican GDP growth affects healthcare spending capacity and government reimbursement budgets, creating modest cyclical exposure.
Rising interest rates have moderate negative impact through higher working capital financing costs, as the business requires substantial inventory and receivables financing. With 0.18x debt/equity, balance sheet leverage is modest, limiting direct debt service pressure. However, higher rates can compress valuation multiples for low-growth distribution businesses and increase the discount rate applied to future cash flows.
Moderate exposure to credit conditions through customer payment terms. Hospitals and institutional customers typically operate on 60-90 day payment cycles, creating accounts receivable risk during credit tightening. Supplier payment terms provide natural hedge, but deteriorating credit conditions can strain working capital and require increased reliance on short-term financing facilities.
value - The stock trades at 0.4x price/sales and 5.0x EV/EBITDA, well below typical healthcare multiples, attracting value investors seeking stable cash flow businesses at discounted valuations. The 0.1% FCF yield and negative recent returns suggest limited appeal to growth or momentum investors. Dividend-focused investors may be attracted if the company initiates or increases distributions, though current FCF generation is constrained by high capex.
moderate - Pharmaceutical distribution businesses typically exhibit lower volatility than broader markets due to non-discretionary demand, but Mexican market exposure and currency fluctuations create additional volatility. Recent performance shows modest drawdowns (-6.3% over 1 year), consistent with defensive healthcare characteristics tempered by emerging market risk.
